Compounded semaglutide is still available through some provider and pharmacy pathways as of August 2026. In April, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from a list used by certain outsourcing facilities. The proposal is not final. Here is what it does and does not change for patients.
Written by Jen, BSN, RN, Clinical Aesthetics Injector. Medically reviewed by Josh Allen, D.O., Medical Director, InjectCo MedSpa. Last updated August 2026.
On April 30, 2026, the FDA announced a proposal not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List. The agency said it did not identify a clinical need for outsourcing facilities to compound these medications from bulk drug substances. The proposal was published in the Federal Register on May 1, 2026.
The 503B Bulks List identifies substances that registered outsourcing facilities may use for compounding under specific federal conditions. After reviewing nominations for the three GLP-1 medications, the FDA proposed not adding them to the list. According to the Federal Register notice, the agency will consider public comments before reaching a final decision.
The comment period closed on July 30, 2026, after an extension. As of August 2026, the FDA has not issued a final determination. The proposal therefore, does not create an immediate or blanket ban on compounded semaglutide. Its stated scope concerns 503B outsourcing facilities that compound from bulk drug substances, not every form of compounding in every setting.
The proposal covers liraglutide as well as semaglutide and tirzepatide, although many summaries have focused only on the two newer medications.
This action comes amid increased FDA scrutiny of how compounded GLP-1 medications are marketed. On March 3, 2026, the agency announced warning letters to 30 telehealth companies. The cited concerns included claims suggesting compounded products were equivalent to FDA-approved medications and marketing that did not clearly identify the pharmacy preparing the medication.
For patients, the practical takeaway is to look beyond marketing claims and verify the details of their prescription. Ask which pharmacy compounds the medication, what formulation it contains, which regulatory pathway applies, and what options the provider will review if the FDA’s position changes.
The April proposal did not require patients to stop treatment when it was announced. The close of the comment period also did not make the proposal final. Nothing in those two events should prompt you to skip an injection, change the amount, or create a new dosing schedule on your own.
Contact the provider managing your prescription before making any change. Ask how your medication is sourced and whether a final determination could affect your plan.
You can use this question script:
We do not know what the FDA’s final determination will be or when it will be issued. If finalized as written, it would change the 503B bulk-list status of the three substances. The effect on a patient would depend on the facility, prescription pathway, and any transition guidance.
Know your medication source and alternatives before a change becomes urgent. If you are considering a schedule change, read about taking semaglutide every other week and speak with your provider first.
Brand-name and compounded semaglutide may contain a form of the same active ingredient, but they are not interchangeable categories. The following distinctions explain how each product is made and regulated, what FDA oversight does and does not cover, and why the form of semaglutide used matters.
Brand-name semaglutide is an FDA-approved product made in standardized formulations and doses. The agency reviewed evidence for its specific indication, safety, effectiveness, and manufacturing quality before marketing.
Compounded semaglutide is prepared by a compounding pharmacy or outsourcing facility through an applicable prescription and legal pathway. It is not an FDA-approved product or generic. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
The options follow different pathways. FDA-approved semaglutide is reviewed as a finished drug product. Traditional 503A pharmacies generally prepare prescriptions for identified patients and are primarily state-regulated. Registered 503B outsourcing facilities face federal requirements and FDA oversight, but their compounded products are not FDA-approved.
FDA-approved products use semaglutide base. The FDA says semaglutide sodium and acetate are different active ingredients and that it is unaware of a lawful basis for using the salts in compounding. It also lacks information showing the same chemical and pharmacologic properties.
Any compounded semaglutide brand-name comparison should start with regulatory status, not price.
| Category | Brand-Name Semaglutide | Compounded Semaglutide |
| Regulatory status | FDA-approved for specific uses. | Not FDA-approved or an approved generic. |
| Oversight | Finished product and manufacturing follow FDA requirements. | Varies between 503A pharmacies and 503B facilities. |
| Formulation | Standardized and contains semaglutide base. | Concentration and ingredients may vary by pharmacy. |
| Evidence base | Product-specific studies support approved uses. | Each formulation has not completed FDA review. |
| Cost | Depends on product, insurance, and assistance. | Usually self-pay through a pharmacy or program. |
| Availability | Depends on eligibility, coverage, and distribution. | Depends on the prescription, pharmacy, and legal pathway. |
Compounded semaglutide may have a pharmacologic effect when it contains the appropriate active ingredient and is accurately prepared and dosed. However, the FDA has not evaluated an individual compounded formulation for safety, effectiveness, quality, or equivalence to an approved product.
That distinction prevents a provider from assuming that every compounded preparation will perform like an FDA-approved version. Formulation, concentration, storage, dosing accuracy, and patient adherence can all affect treatment. Individual results vary.
Your provider should explain how semaglutide is dosed for your prescription and how response and side effects will be monitored.
No medication is safe for every person. Compounded medications may meet a patient need, but they do not receive the same premarket review as FDA-approved products.
Before prescribing, the provider should review your health history, other medications, contraindications, side effects, and dosing. You should know the pharmacy, concentration, form of semaglutide, storage instructions, and contact for dosing or quality concerns.
Be cautious when marketing calls a compounded medication the same as an approved product, describes it as a generic, or hides the pharmacy. The FDA cited these issues in March 2026.
Ask an InjectCo provider about the formulation, pharmacy source, dosing instructions, regulatory status, and alternatives for your treatment plan.
A provider may discuss compounded semaglutide when an individualized prescription is clinically appropriate and the patient understands that the product is not FDA-approved. The conversation may include:
An FDA-approved product may be the more appropriate choice for someone who wants:
The InjectCo compounded semaglutide program includes a secure medical evaluation, medication when prescribed, delivery supplies, and provider follow-up. Eligibility is not automatic, and a licensed provider determines whether treatment is clinically appropriate.
Review InjectCo’s transparent pricing and ask what the quoted amount includes before enrolling. Insurance coverage, pharmacy availability, and program terms can change.
Review what is included, how the medication is sourced, and what alternatives may be available before choosing a program.
At InjectCo, our semaglutide program begins with a secure medical evaluation. A licensed provider reviews your history, current medications, treatment goals, and eligibility before deciding whether compounded semaglutide is appropriate.
If medication is prescribed, the team explains the pharmacy source, formulation, concentration, dosing instructions, storage, and follow-up plan. Current patients can also ask how a future FDA determination could affect access and which alternatives would be reviewed if the program changes.
Review your prescription source, formulation, dosing plan, and possible next steps with a licensed InjectCo provider.
Most of the confusion around compounded semaglutide lands on the same handful of questions. The ones below cover whether it has been banned, whether it is going away, what availability looks like right now, and what the FDA proposal said.
No. Compounded semaglutide has not been universally banned, and the 503B proposal is not a blanket prohibition on all forms of compounding. However, semaglutide is no longer on the FDA drug shortage list, so pharmacies and outsourcing facilities cannot continue producing routine copies under the broad shortage-related conditions that previously applied.
That has not been determined. Availability will depend on the FDA’s final decision, the type of pharmacy involved, the prescription pathway, and whether a patient has a clinical need that an available FDA-approved product cannot meet. Patients should ask their providers how regulatory changes may affect their prescriptions instead of assuming that all compounded options will disappear.
Compounded semaglutide may remain available in limited circumstances, but it should not be treated as a routine substitute for an FDA-approved product. Under section 503A, a state-licensed pharmacy may compound for an identified patient when the prescription and product meet applicable legal requirements. A licensed provider must determine whether a compounded medication is appropriate and legally available for your specific needs.
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The agency said it did not find sufficient evidence of a clinical need for 503B outsourcing facilities to compound these medications from bulk substances. The proposal appeared in the Federal Register on May 1, and the public comment period was later extended through July 30, 2026.
Compounded semaglutide is not automatically unsafe, but it does not undergo FDA premarket review for safety, effectiveness, or manufacturing quality. Risks may include incorrect concentrations, dosing errors, improper storage, contamination, or the use of an inappropriate active ingredient. The FDA recommends using an approved medication when it is available and appropriate.
FDA-approved semaglutide products use semaglutide base. Semaglutide sodium and semaglutide acetate are different active ingredients, and the FDA says it does not have information showing that these salt forms have the same chemical and pharmacologic properties. The agency is also unaware of a lawful basis for using these salts in compounding.
Do not stop treatment, change your dose, or adjust your schedule solely because of a headline. Ask your provider to confirm the dispensing pharmacy, exact formulation, concentration, dosing units, storage instructions, and whether the product uses semaglutide base. You should also discuss what happens if your current pharmacy can no longer fill the prescription.
Brand-name semaglutide is an FDA-approved finished drug made in standardized formulations and doses for specific indications. Compounded semaglutide is prepared through a pharmacy or outsourcing pathway for particular circumstances and is not FDA-approved or an approved generic. Its formulation, concentration, delivery device, and instructions may differ depending on the prescription and compounder.
The FDA proposal deserves attention, but it is not a final rule or a reason to change treatment without medical guidance. Verify who prepares your medication, which form it contains, and what your provider recommends if access changes.
Individual results vary. Continue following your current prescription unless the licensed provider managing your care advises otherwise.
Talk with an InjectCo provider about your current prescription, the FDA proposal, and the options that may fit your medical needs.
This article is for general education and is not medical advice. It does not replace a consultation with a licensed provider. Regulatory status described here is current as of August 2026 and may change. Individual results vary. Do not start, stop, or change any prescription medication without the provider managing your care.
Dr. Allen earned his Doctor of Osteopathic Medicine at Lake Erie College of Osteopathic Medicine and completed his emergency medicine residency with Texas A&M. As Medical Director, he reviews InjectCo’s treatments, protocols, and patient education content for accuracy and safety across all nine Texas locations.
days day
hours hour
minutes minute
seconds second
50,000+
5-Star
75+ Years
Licensed
